Indication
Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections.
Medicine details
- Medicine name:
- delafloxacin (Quofenix)
- SMC ID:
- SMC2453
- Pharmaceutical company
- Menarini Pharmaceuticals UK
- BNF chapter
- Infections
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 02 May 2022